Results 181 to 190 of about 2,901,254 (317)

Risk factors for community-acquired pressure injuries: Findings from a large-scale Asian case-control study. [PDF]

Int J Nurs Stud Adv
Aloweni F, Siow KCE, Gunasegaran N, Lim GH, Ang SY, Østbye T.   +5 more
europepmc   +1 more source

Retinal detachment in patients with acquired immunodeficiency syndrome [PDF]

, 1994
Bogner, Johannes R., Geier, Stephan A., Schmidt-Kittler, H., Sadri, Ifna, Goebel, Frank-Detlef   +4 more
core  

Optimal management of common acquired melanocytic nevi (moles): current perspectives

, 2014
Kabir Sardana, Payal Chakravarty, Khushbu Goel Department of Dermatology and STD, Maulana Azad Medical College and Lok Nayak Hospital, New Delhi, Delhi, India Abstract: Although common acquired melanocytic nevi are largely benign, they are probably one ...
Chakravarty P, Sardana K, Goel K
core  

Interaction of HS1BP3 with cortactin modulates TKS5 localisation, cell secretion and cancer malignancy

Molecular Oncology, EarlyView.
Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen, Kristiane Søreng, Chiara Veroni, Laura Trachsel‐Moncho, Nagham Asp, Robin Gaupset, Lars Gustav Lyckander, Helene Knævelsrud, Lars Eftang, Anne Simonsen   +9 more
wiley   +1 more source

Deep Learning-Based Synthetic Contrast-Enhanced Breast MRI for Monitoring Response to Neoadjuvant Therapy. [PDF]

Cancers (Basel)
Sujichantararat S, Biswas D, Kazerouni AS, Tsang ED, Sathe A, Hippe DS, Park VY, Chung M, Specht JM, Dintzis SM, Rahbar H, Holmes JH, Huang W, Partridge SC.   +13 more
europepmc   +1 more source

ESR1 methylation and ESR1 mutations in circulating tumor cells (CTCs) and paired plasma‐cfDNA of advanced breast cancer patients: A feasibility proof‐of‐concept study

Molecular Oncology, EarlyView.
Circulating tumor cells (CTCs) and plasma cell‐free DNA (cfDNA) were analyzed to detect ESR1 mutations and methylation in patients with advanced breast cancer. CTC‐derived DNA showed higher sensitivity for mutation detection and revealed complementary genetic and epigenetic alterations, highlighting the added value of CTC analysis for understanding ...
Dimitra Stergiopoulou, Athina Markou, Eleonora Nicolo, Mara S Serafini, Qiang Zhang, Youbin Zhang, Lorenzo Gerratana, Andrew A. Davis, Huiping Liu, William J Gradishar, Carolina Reduzzi, Massimo Cristofanilli, Evi Lianidou   +12 more
wiley   +1 more source

Improving image quality in terbium-161 phantom imaging: Quantitative evaluation of DEW and TEW scatter correction methods. [PDF]

J Appl Clin Med Phys
Can M, Çapa Kaya G, Gümüşer G, Parlak Y.   +3 more
europepmc   +1 more source

Interpreting the effects of DNA polymerase variants at the structural level

Molecular Oncology, EarlyView.
Using MAVISp and molecular dynamics simulations, we analyzed over 60 000 missense variants in POLE and POLD1 from ClinVar, COSMIC, cBioPortal, and saturation mutagenesis. Identified mechanistic indicators, including stability, binding, and long‐range, enable structural interpretation, providing ACMG‐like evidence for possible reclassification of VUS ...
Matteo Arnaudi, Karolina Krzesińska, Ludovica Beltrame, Pablo Sánchez‐Izquierdo Besora, Matteo Tiberti, Mef Nilbert, Anna Rohlin, Elena Papaleo   +7 more
wiley   +1 more source

Perspective of People Living With HIV and Healthcare Workers on the Uptake, Barriers, and Benefits of Multimonth Dispensing: A Qualitative Systematic Review. [PDF]

AIDS Res Treat
Okezie CW, Badru OA, Ibitoye FA, Edeh JC, Adeagbo OA.   +4 more
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source